A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
about
FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.The therapeutic potential of cell cycle targeting in multiple myeloma.Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.
P2860
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A phase II study of AT9283, an ...... clinical trials group IND.191.
@en
A phase II study of AT9283, an ...... clinical trials group IND.191.
@nl
type
label
A phase II study of AT9283, an ...... clinical trials group IND.191.
@en
A phase II study of AT9283, an ...... clinical trials group IND.191.
@nl
prefLabel
A phase II study of AT9283, an ...... clinical trials group IND.191.
@en
A phase II study of AT9283, an ...... clinical trials group IND.191.
@nl
P2093
P2860
P1433
P1476
A phase II study of AT9283, an ...... clinical trials group IND.191
@en
P2093
Alli Murugesan
Ashley M DiPasquale
Donna E Reece
Jean Powers
Joana Sederias
Johan Lategan
John F Lyons
Lesley K Seymour
Nizar J Bahlis
P2860
P304
P356
10.3109/10428194.2015.1091927
P577
2015-10-15T00:00:00Z